Stage IIIC endometrioid corpus cancer includes distinct subgroups
- PMID: 12468351
- DOI: 10.1006/gyno.2002.6789
Stage IIIC endometrioid corpus cancer includes distinct subgroups
Abstract
Objective: Because stage IIIC corpus cancer is a heterogeneous substage, the outcomes of patients with stage IIIC disease were assessed according to the extent of extrauterine disease.
Methods: From 1984 through 1993, 51 patients with surgical stage IIIC corpus cancer were treated at our institution; 5 patients had tumors with nonendometrioid histologic features and were excluded from the analyses. Of the 46 patients with endometrioid carcinoma, 22 had lymph nodes as the only site of extrauterine disease (stage IIIC(0)) and 24 also had peritoneal cytologic, uterine serosal, adnexal, or vaginal involvement or a combination of these (stage IIIC(ab)). The mean number of lymph nodes removed was 18 pelvic and 8 aortic nodes. Median follow-up for surviving patients was 84 months.
Results: Patients with stage IIIC(0) cancer had a 5-year cause-specific survival (CSS) of 72% and a 5-year recurrence-free survival (RFS) of 68%, and those with stage IIIC(ab) had a CSS of 33% and an RFS of 25% (P < 0.01). Of the 22 patients with stage IIIC(0) endometrioid cancer, 21 had adjuvant radiotherapy (1 also received chemotherapy) and 1 was not treated. Relapse occurred in 7 (32%) patients, with only 1 having an initial failure component outside the node-bearing areas (lung). Of the 24 patients with stage IIIC(ab) cancer, 16 received adjuvant radiotherapy (1 had concomitant chemotherapy), 2 had chemotherapy, 4 had hormonal therapy, and 2 were not treated. We observed 16 recurrences (67%). Of the 14 patients with known initial sites of failure, 9 had an extranodal failure component.
Conclusion: Assessment of CSS, RFS, and sites of relapse suggests that FIGO surgical stage IIIC endometrioid corpus cancer includes two distinct and readily separable subgroups: (1) stage IIIC(0), nodal involvement only, and (2) stage IIIC(ab), nodal plus cytologic, uterine serosal, adnexal, or vaginal involvement, or a combination of these. Our results also suggest that different treatment strategies are needed for these subgroups.
Similar articles
-
Assessment of prognostic factors in stage IIIA endometrial cancer.Gynecol Oncol. 2002 Jul;86(1):38-44. doi: 10.1006/gyno.2002.6713. Gynecol Oncol. 2002. PMID: 12079298
-
Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer.Gynecol Oncol. 2019 Jul;154(1):22-28. doi: 10.1016/j.ygyno.2019.05.002. Epub 2019 May 17. Gynecol Oncol. 2019. PMID: 31109659 Free PMC article.
-
FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes.Gynecol Oncol. 2009 Aug;114(2):273-8. doi: 10.1016/j.ygyno.2009.04.013. Epub 2009 May 9. Gynecol Oncol. 2009. PMID: 19428094
-
Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1272-6. doi: 10.1016/s0360-3016(02)04404-8. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654437 Review.
-
Dedifferentiated endometrioid adenocarcinoma of the uterus: a case report.Eur J Gynaecol Oncol. 2016;37(3):426-9. Eur J Gynaecol Oncol. 2016. PMID: 27352580 Review.
Cited by
-
Prognostic model for the exemption of adjuvant chemotherapy in stage IIIC endometrial cancer patients.Front Endocrinol (Lausanne). 2022 Oct 26;13:989063. doi: 10.3389/fendo.2022.989063. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36387854 Free PMC article.
-
An analysis of the significance of the lymph node ratio and extracapsular involvement in the prognosis of endometrial cancer patients.Contemp Oncol (Pozn). 2022;26(2):144-149. doi: 10.5114/wo.2022.118243. Epub 2022 Jun 30. Contemp Oncol (Pozn). 2022. PMID: 35903209 Free PMC article.
-
Genomic landscape of advanced endometrial cancer analyzed by targeted next-generation sequencing and the cancer genome atlas (TCGA) dataset.J Gynecol Oncol. 2022 May;33(3):e29. doi: 10.3802/jgo.2022.33.e29. Epub 2022 Jan 24. J Gynecol Oncol. 2022. PMID: 35128859 Free PMC article.
-
Subdivision of IIIC Stage for Endometrioid Carcinoma to Better Predict Prognosis and Treatment Guidance.Front Oncol. 2020 Jul 31;10:1175. doi: 10.3389/fonc.2020.01175. eCollection 2020. Front Oncol. 2020. PMID: 32850338 Free PMC article.
-
Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: International expert consensus recommendations.Gynecol Oncol. 2020 Aug;158(2):244-253. doi: 10.1016/j.ygyno.2020.06.486. Epub 2020 Jun 15. Gynecol Oncol. 2020. PMID: 32563593 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources